Efficacy and toxicity of trastuzumab combined vinorelbine in 21 patients with HER2 overexpressing metastatic breast cancer / 南方医科大学学报
Journal of Southern Medical University
;
(12): 1707-1709, 2008.
Article
in Chinese
| WPRIM
| ID: wpr-340742
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and toxicity in patients with HER2 overexpressing metastatic breast cancer.</p><p><b>METHODS</b>Twenty-one patients with HER2 overexpressing metastatic breast cancer entered into the study. Trastuzumab (8 mg/kg day 1, then 6 mg/kg every 21 days or 4 mg/kg, then 2 mg/kg every week) and vinorelbine (25 mg/m(2)) was given on days 1 and 8 every 21 days.</p><p><b>RESULTS</b>Overall 56 cycles were given to the 21 patients enrolled into the study (mean 2, range 1-6). All can be evaluated. The response rate was 33.33% (7/21), one patient achieved complete response (CR), six patients achieved partial response (PR), four patients achieved stable disease (SD), ten patients achieved progressive disease (PD)]. The median time to progression was 3.5 months. One year overall survival was 33%. The major toxicity was myelosuppression and peripheral neuritis. A few patients were observed with fever and lower grade cardiac failure.</p><p><b>CONCLUSION</b>The combination of trastuzumab and vinorelbine is an effective and well tolerated therapy in patients with pretreated metastatic breast cancer.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Thrombocytopenia
/
Vinblastine
/
Vomiting
/
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Survival Analysis
/
Treatment Outcome
/
Carcinoma, Ductal, Breast
/
Receptor, ErbB-2
Limits:
Adult
/
Aged
/
Female
/
Humans
Language:
Chinese
Journal:
Journal of Southern Medical University
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS